To see the other types of publications on this topic, follow the link: EGCH 350.
Journal articles on the topic 'EGCH 350'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 29 journal articles for your research on the topic 'EGCH 350.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Fung, Shing-Tack, Cyrus K. Ho, Siu-Wai Choi, Wai-Yuen Chung, and Iris F. F. Benzie. "Comparison of catechin profiles in human plasma and urine after single dosing and regular intake of green tea (Camellia sinensis)." British Journal of Nutrition 109, no. 12 (2012): 2199–207. http://dx.doi.org/10.1017/s0007114512004370.
Full textAbstract:
Green tea (Camellia sinensis) catechin profiles in plasma and urine following single dosing and regular ingestion of green tea are not clear. We performed a placebo-controlled intervention study with sixteen healthy volunteers to determine changes in total and free catechins after a single dose and following 1 week of twice-daily green tea. Blood and urine samples were collected before (fasting) and after (60 and 120 min for blood; 90 and 180 min for urine) drinking 200 ml of 1·5 % (w/v) green tea or water (n 8 each), and fasting samples were again collected after 7 d of 150 ml of 1 % (w/v) supplemental green tea or water twice daily. After a 4-week washout, subjects were crossed onto the other treatment and procedures repeated. Plasma results at 1 h post-ingestion showed elevated (P< 0·05) mean epigallocatechin gallate (EGCG; 310 (sd 117) nmol/l; all in free form), epigallocatechin (EGC; 192 (sd 67) nmol/l; 30 % free) and epicatechin gallate (ECG; 134 (sd 51) nmol/l; 75 % free). Fasting plasma after 7 d of regular intake showed increased (P< 0·05) EGCG (80 v. 15 nmol/l at baseline) and ECG (120 v. 40 nmol/l), with ≥ 90 % of both in their conjugated forms. Total EGC was < 10 nmol/l. Post-ingestion conjugation and renal loss of EGC and epicatechin were rapid and high, but were negligible for EGCG and ECG. In the green tea consumed, the content was EGCG >EGC >ECG, and the acute plasma response mirrored this. However, after chronic consumption there was almost no EGC found in fasting plasma, some EGCG was present, but a rather high level of ECG was maintained.
2
Kim, Myung Jin, Hyung Il Kim, Jin Chung, Tae Sung Jeong, and Hae Ryoun Park. "(-)-Epigallocatechin-3-Gallate (EGCG) Increases the Viability of Serum-Starved A549 Cells Through Its Effect on Akt." American Journal of Chinese Medicine 37, no. 04 (2009): 723–34. http://dx.doi.org/10.1142/s0192415x09007193.
Full textAbstract:
The effect of epigallocatechin gallate (EGCG) on cell survival was studied by using serum-starved A549 non-small cell lung carcinoma (NSCLC) cells. A MTT assay showed that EGCG significantly increased the viability of serum-starved A549 cells compared to the control cells, though EGCG at high concentration (~300 μM) had no protective effect against serum withdrawal-induced cell apoptosis. Western blots showed increased immunoreactivity for phospho-Akt and phospho-GSK3β in EGCG-treated cells. To determine the mechanism for Akt phosphorylation, cells were pretreated with various kinase inhibitors before exposure to EGCG. Only LY294002 inhibited Akt activation induced by EGCG, implying that EGCG-induced Akt activation is PI3K dependent. Both phospho-Raf-1 and Raf-1 proteins were significantly decreased, whereas B-raf expression was not altered. This suggests that the Raf kinases have no role in the increased cell survival caused by EGCG. This study has shown that EGCG protects A549 cells from apoptosis induced by serum deprivation via Akt activation and this protective effect may limit the clinical use of EGCG in treating and preventing NSCLC.
3
Moreno-Vásquez, María J., Maribel Plascencia-Jatomea, Saúl Sánchez-Valdes, et al. "Characterization of Epigallocatechin-Gallate-Grafted Chitosan Nanoparticles and Evaluation of Their Antibacterial and Antioxidant Potential." Polymers 13, no. 9 (2021): 1375. http://dx.doi.org/10.3390/polym13091375.
Full textAbstract:
Nanoparticles based on chitosan modified with epigallocatechin gallate (EGCG) were synthetized by nanoprecipitation (EGCG-g-chitosan-P). Chitosan was modified by free-radical-induced grafting, which was verified by Fourier transform infrared (FTIR). Furthermore, the morphology, particle size, polydispersity index, and zeta potential of the nanoparticles were investigated. The grafting degree of EGCG, reactive oxygen species (ROS) production, antibacterial and antioxidant activities of EGCG-g-chitosan-P were evaluated and compared with those of pure EGCG and chitosan nanoparticles (Chitosan-P). FTIR results confirmed the modification of the chitosan with EGCG. The EGCG-g-chitosan-P showed spherical shapes and smoother surfaces than those of Chitosan-P. EGCG content of the grafted chitosan nanoparticles was 330 μg/g. Minimal inhibitory concentration (MIC) of EGCG-g-chitosan-P (15.6 μg/mL) was lower than Chitosan-P (31.2 μg/mL) and EGCG (500 μg/mL) against Pseudomonas fluorescens (p < 0.05). Additionally, EGCG-g-chitosan-P and Chitosan-P presented higher Staphylococcus aureus growth inhibition (100%) than EGCG at the lowest concentration tested. The nanoparticles produced an increase of ROS (p < 0.05) in both bacterial species assayed. Furthermore, EGCG-g-chitosan-P exhibited higher antioxidant activity than that of Chitosan-P (p < 0.05) in 2,2′-azino-bis (3-ethyl-benzothiazoline-6-sulfonic acid) (ABTS), 2,2-diphenyl-1-picrylhydrazyl radical (DPPH) and ferric-reducing antioxidant power assays. Based on the above results, EGCG-g-chitosan-P shows the potential for food packaging and biomedical applications.
4
Mielgo-Ayuso, Juan, Lurdes Barrenechea, Pilar Alcorta, Eider Larrarte, Javier Margareto, and Idoia Labayen. "Effects of dietary supplementation with epigallocatechin-3-gallate on weight loss, energy homeostasis, cardiometabolic risk factors and liver function in obese women: randomised, double-blind, placebo-controlled clinical trial." British Journal of Nutrition 111, no. 7 (2013): 1263–71. http://dx.doi.org/10.1017/s0007114513003784.
Full textAbstract:
The aim of the present study was to examine the effects of green tea epigallocatechin-3-gallate (EGCG) on changes in body composition, energy and substrate metabolism, cardiometabolic risk factors and liver function enzymes after an energy-restricted diet intervention in obese women. In the present randomised, double-blind, placebo-controlled study, eighty-three obese (30 kg/m2>BMI < 40 kg/m2) pre-menopausal women consumed 300 mg/d of EGCG or placebo (lactose). We measured body weight and adiposity (dual-energy X-ray absorptiometry), energy expenditure and fat oxidation rates (indirect calorimetry), blood lipid levels (TAG, total cholesterol, LDL-cholesterol and HDL-cholesterol), insulin resistance, C-reactive protein and liver function markers (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, γ-glutamyltransferase, urea, bilirubin and 2-keto[1-13C]isocaproate oxidation) before and after the intervention in the EGCG and control groups. We did not find any significant difference in the changes in body weight ( − 0·3 kg, 95 % CI − 5·0, 4·3), fat mass ( − 0·7 kg, 95 % CI − 3·5, 2·1), energy (0·3 kJ/kg per d, 95 % CI − 3·1, 2·7) and fat ( − 0·1 g/min, 95 % CI − 0·03, 0·01) metabolism, homeostasis assessment model for insulin resistance (0·2, 95 % CI − 0·2, 0·7), total cholesterol ( − 0·21 mmol/l, 95 % CI − 0·55, 0·13), LDL-cholesterol ( − 0·15 mmol/l, 95 % CI − 0·50, 0·20), TAG ( − 0·14 mmol/l, 95 % CI − 0·56, 0·29) and liver function markers between the EGCG and control groups. In conclusion, the present results suggest that dietary supplementation with 300 mg/d of EGCG for 12 weeks did not enhance energy-restricted diet-induced adiposity reductions, and did not improve weight-loss-induced changes in cardiometabolic risk factors in obese Caucasian women. The intake of 300 mg/d of EGCG for 12 weeks did not cause any adverse effect on liver function biomarkers.
5
Bérubé-Parent, Sonia, Catherine Pelletier, Jean Doré, and Angelo Tremblay. "Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men." British Journal of Nutrition 94, no. 3 (2005): 432–36. http://dx.doi.org/10.1079/bjn20051502.
Full textAbstract:
It has been reported that green tea has a thermogenic effect, due to its caffeine content and probably also to the catechin, epigallocatechin-3-gallate (EGCG). The main aim of the present study was to compare the effect of a mixture of green tea and Guarana extracts containing a fixed dose of caffeine and variable doses of EGCG on 24 h energy expenditure and fat oxidation. Fourteen subjects took part to this randomized, placebo-controlled, double-blind, cross-over study. Each subject was tested five times in a metabolic chamber to measure 24 h energy expenditure, substrate oxidation and blood pressure. During each stay, the subjects ingested a capsule of placebo or capsules containing 200 mg caffeine and a variable dose of EGCG (90, 200, 300 or 400 mg) three times daily, 30 min before standardized meals. Twenty-four hour energy expenditure increased significantly by about 750 kJ with all EGCG–caffeine mixtures compared with placebo. No effect of the EGCG–caffeine mixture was observed for lipid oxidation. Systolic and diastolic blood pressure increased by about 7 and 5 mmHg, respectively, with the EGCG–caffeine mixtures compared with placebo. This increase was significant only for 24 h diastolic blood pressure. The main finding of the study was the increase in 24 h energy expenditure with the EGCG–caffeine mixtures. However, this increase was similar with all doses of EGCG in the mixtures.
6
Hadi, Said, Meysam Alipour, Vahideh Aghamohammadi, et al. "Improvement in fasting blood sugar, anthropometric measurement and hs-CRP after consumption of epigallocatechin-3-gallate (EGCG) in patients with type 2 diabetes mellitus." Nutrition & Food Science 50, no. 2 (2019): 348–59. http://dx.doi.org/10.1108/nfs-04-2019-0126.
Full textAbstract:
Purpose The epigallocatechin gallate (EGCG) effect in diabetes has been investigated in animal studies, but results of clinical trials are inconsistent. Thus, this study aims to evaluate the effects of EGCG supplementation in patients with type 2 diabetes mellitus (T2DM). Design/methodology/approach A total of 50 patients with T2DM were recruited in a double-blind, randomized, placebo-controlled trial. The eligible participants were randomly allocated to EGCG (n = 25) and placebo (n = 25) groups. The EGCG group received two capsules of EGCG (each capsule contained 150 mg; Shari Made®, Iran) and placebo group was administered two capsules of placebo (starch) for eight weeks. A three-day 24-h dietary recall and anthropometric and laboratory measurements were carried out at the beginning and the end of the study. Findings At the end of the trial, weight and body mass index (BMI) were decreased significantly in both groups, but the reduction was not statistically significant between the two groups. Fasting blood sugar decreased significantly in EGCG group. No significant between-group and within-group differences were found in insulin, homeostatic model assessment of insulin resistance (HOMA-IR) and the quantitative insulin sensitivity check index values. The high-sensitive C-reactive protein (hs-CRP) was significantly reduced in the EGCG group (4.13 ± 0.48-3.93 ± 0.50, p = 0.003) compared to baseline. Originality/value This study showed that consuming 300 mg/day of EGCG for eight weeks in patients with T2DM caused a significant decrease in fasting blood glucose, body weight, BMI and hs-CRP compared to baseline. Therefore, the EGCG supplementation may improve glycemic control, anthropometric and inflammation status in T2DM.
7
Nascimento, André Márcio do, Priscila Tavares Guedes, Rachel Oliveira Castilho, and Cristina Duarte Vianna-Soares. "Stryphnodendron adstringens (Mart.) Coville (Fabaceae) proanthocyanidins quantitation by RP-HPLC." Brazilian Journal of Pharmaceutical Sciences 49, no. 3 (2013): 549–58. http://dx.doi.org/10.1590/s1984-82502013000300016.
Full textAbstract:
Stryphnodendron adstringens (Mart.) Coville (barbatimão) is a tree belonging to the Fabaceae family, and it is commonly found in the southeastern Brazilian cerrado. The stem bark of this tree is traditionally used as an anti-inflammatory and antiseptic agent to treat leucorrhea and diarrhea, as well as to promote wound healing (owing to the presence of proanthocyanidins). Proanthocyanidins were obtained from the ethanolic extract of S. adstringens stem bark and assessed by reversed phase-high performance liquid chromatography with an ultraviolet/diode array detector. The identified compounds included gallic acid, catechin, gallocatechin (GC), epigallocatechin, and epigallocatechin gallate (EGCG). The selected markers, GC and EGCG, were simultaneously used for chromatographic validation (linearity range: 30-330 ng, equivalent to 3-33 µg/mL; r>0.998). The method showed precision (intra-day relative standard deviation [RSD]: 1.72% for GC; 1.16% for EGCG; inter-day RSD: 1.74%-2.60% for both markers), accuracy, robustness, and selectivity. The limits of detection and quantitation were 0.29 µg/ml and 0.89 µg/ml for GC, and 0.88 µg/mL and 2.67 µg/mL for EGCG, respectively. In addition, S. obovatum was evaluated and showed an average of 12.2 µg/mL for GC (equivalent to 1.22% w/w) and 14.2 µg/mL for EGCG (equivalent to 1.42% w/w) in the ethanolic extract. The quantitative results were compared to those obtained for S. adstringens, which showed that the markers are present in both species.
8
Yelins’ka, A. M., and V. O. Kostenko. "SYNERGISTIC EFFECT OF QUERCETIN AND EPIGALLOCATECHIN-3-GALLATE AS AGENTS TO PREVENT CONNECTIVE TISSUE DISINTEGRATION IN THE PERIODONTIUM OF RATS UNDER SYSTEMIC AND LOCAL ADMINISTRATION OF LIPOPOLISACCHARIDE OF SALMONELLA TYPHI." Medical and Ecological Problems 23, no. 5-6 (2019): 42–44. http://dx.doi.org/10.31718/mep.2019.23.5-6.07.
Full textAbstract:
The aim of the present study was to investigate the co-effect produced by water-soluble form of quercetin and epigallocatechin-3-gallate (EGCG) on biochemical markers of periodontal organic matrix depolimerization under systemic administration and local application of S. typhi lipopolisaccharide (LPS). The studies were conducted on 30 white rats of the Wistar line weighing 180-220 g, divided into 5 groups: the 1st included intact animals, the 2nd was made up of animals after the combined systemic and local LPS administration, the 3rd and 4th groups included animals, which were being given injections with water-soluble form of quercetin (10 mg / kg) and EGCG (21.1 mg / kg) respectively 3 times a week, starting on the 30th day of the systemic LPS administration, and the 5th group involved rats, which were injected with co-administered water-soluble form of quercetin and EGCG. It has been found out that the co-effect produced by quercetin and EGCG under systemic and local LPS administration is accompanied with reduced concentration of N-acetylneuraminic acid (NANA) by 31.8 and 32.8% respectively in the soft periodontal tissues compared with values for the animals received separate quercetin and EGCG during the experiment. However, no differences have been detected between the groups exposed to combined or separate action of the above mentioned agents in the experiment when assessing free hydroxyproline (FHP) and glycosaminoglycans (GAGs) content in the soft tissues of periodontium. At the same time combined use of quercetin and EGCG under experimental conditions led to the decrease in the FHP content in the alveolar bone by 24.5 and 20.2% respectively compared with values for the animals received separate quercetin and EGCG. NANA concentration was reduced by 35.0 and 41.3% respectively. Thus, the co-administration of water-soluble form of quercetin and epigallocatechin-3-gallate under systemic and local introducing of S. typhi lipopolysaccharide has been proven to be more effective means for preventing and correcting periodontal connective tissue disruption than this occurs at separate administration of each of the polyphenols.
9
Lesnick, Connie, Neil E. Kay, Betsy LaPlant, and Tait D. Shanafelt. "The Green Tea Extract EGCG Demonstrates Synergist Activity against CLL B-Cells When Combined with Fludarabine and Chlorambucil." Blood 114, no. 22 (2009): 3452. http://dx.doi.org/10.1182/blood.v114.22.3452.3452.
Full textAbstract:
Abstract Abstract 3452 Poster Board III-340 PURPOSE Chronic Lymphocytic Leukemia (CLL) is incurable with current chemotherapy treatments. Epigallocatechin 3 gallate (EGCG), the major catechin in green tea, has been shown to induced caspase-dependent death CLL B-cells and down regulate anti-apoptotic proteins (Mcl-1; XIAP) known to increase the resistance of CLL B-cells to apoptosis (Blood 104:788-94). In Phase I testing for patients with early stage CLL (Rai 0-II), EGCG treatment was well tolerated and induced a decline in absolute lymphocyte count (ALC) and/or lymphadenopathy in the majority of treated patients without myelosuppression (JCO 27:3808-14). Although peak plasma EGCG levels were not measured in this study, trough plasma EGCG levels as high as 4 μg/ML were achieved. To further our understanding of the potential clinical applications of EGCG for patients with CLL, we evaluated the effects of EGCG on the viability of CLL B-cells when combined with fludarabine (F), chlorambucil (C), or fludarabine and chlorambucil in combination (FC). METHODS Primary CLL B-cells were treated with various doses of F (0.25-1 μM), C (10-30 μM), or FC either alone or in combination EGCG (50 to 100 μM). In other experiments, CLL B-cells were treated with various doses of F (0.25-1 μM), C (10-30 μM), or FC with or without a fixed dose of EGCG known to be physiologically achievable in vivo (4 μM). After 48 hours (experiments with C +/− EGCG) or 72 hours (experiments with F +/− EGCG or FC +/− EGCG), cells were harvested, stained with annexin/PI and viability analyzed by flow cytometry. After concentration-effect curves were generated for each agent, data were also analyzed using the CalcuSyn software program (Biosoft, Cambridge, UK) which uses the method of Chou and Talalay to determine whether combination treatment yielded greater effects than expected from summation alone. A combination index (CI) of 0.8 – 1.2 indicates an additive effect, a CI >1.2 indicates an antagonistic effect and a CI <0.8 indicates a synergistic effect. RESULTS Primary leukemic B-cells from 56 CLL patients were cultured in vitro with various doses of EGCG alone or in combination with F, C, or FC. The median LD50 was approximately 100 μM. Although % apoptotic cells at the 100 μM EGCG dose did not vary based on Rai stage, ZAP-70 status, IGHV gene mutation status, or cytogenetic abnormalities by FISH, CD38 negative patients had greater cell death than CD38 positive patients (67% vs. 49%; p=0.05). In co-titration experiments, EGCG had an additive (CI 0.8 – 1.2) or synergistic (CI <0.8) effect on apoptosis when combined with C in the majority of patients (13/15; additive 11, synergism 2) with rare individuals demonstrating antagonism (CI >1.2; 2/15). The effects of EGCG when combined with F in co-titration experiments were more variable with a relatively even distribution between antagonism (8/18), additive effects (4/18), and synergy (6/18). However, co-titration experiments of FC with or without EGCG demonstrated additive or synergistic effect in most patients (8/10; additive 7, synergism 1). Next we evaluated the effect of F (0.25 - 1 μM), C (10 - 30 μM), or FC with or without a fixed dose of EGCG known to be physiologically achievable in vivo (4 μM). This dose of EGCG had an additive or synergistic effect in the majority of samples across the spectrum of dose levels under all 3 conditions (F, C, and FC). For example, at the 10 μM dose of C the addition of 4 μM EGCG had an additive or synergistic effect in 11/14 patients (synergistic 6; additive 5). With F at the 2.5 μM dose level the addition of 4 μM EGCG had an additive or synergistic effect in 13/16 patients (synergistic 7, additive 6). The addition of 4 μM EGCG appeared particularly beneficial when given in combination with FC (Fig.). For example, at F 2.5 μM in combination with C 5 μM the addition of 4 μM EGCG had an additive or synergistic effect in 10/10 patients (synergism 7; additive 3). CONCLUSIONS Physiologically achievable doses of EGCG appear to enhance the efficacy of alkylating agents, purine nucleoside analogues, and alkylating agent/purine analogue combination therapy for the majority of CLL patients on in vitro testing. The favorable toxicity profile of EGCG and lack of myelosuppression with this agent in the phase I trial (JCO 27:3808-14) make it an attractive agent to test in combination with purine analogue and alkylator based chemo-immunotherapy for patients with CLL. Disclosures Kay: Genentech, Celgene, Hospira, Polyphenon Pharma, Sanofi-Aventis: Research Funding; Biogenc-Idec, Celgene, Genentech, genmab: Membership on an entity's Board of Directors or advisory committees. Shanafelt:Genentech: Research Funding; Hospira: Membership on an entity's Board of Directors or advisory committees, Research Funding; Polyphenon Pharma : Patents & Royalties, Research Funding; Celgene: Research Funding; Cephalon: Research Funding; Bayer Health Care Pharmaceuticals: Research Funding.
10
Peek, James, Thomas Shi, and Dinesh Christendat. "Identification of Novel Polyphenolic Inhibitors of Shikimate Dehydrogenase (AroE)." Journal of Biomolecular Screening 19, no. 7 (2014): 1090–98. http://dx.doi.org/10.1177/1087057114527127.
Full textAbstract:
Shikimate dehydrogenase (AroE) is an attractive target for herbicides and antimicrobial agents due to its conserved and essential nature in plants, fungi, and bacteria. Here, we have performed an in vitro screen using a collection of more than 5500 compounds and identified 24 novel inhibitors of AroE from Pseudomonas putida. The IC50 values for the two most potent inhibitors we identified, epigallocatechin gallate (EGCG) and epicatechin gallate (ECG), were 3.0 ± 0.2 µM and 3.7 ± 0.5 µM, respectively. Based on the high level of structural conservation between AroE orthologs, we predicted that the identified compounds would also inhibit AroE enzymes from other organisms. Consistent with this hypothesis, we found that EGCG and ECG inhibit the AroE domain of the bifunctional dehydroquinate dehydratase-shikimate dehydrogenase (DHQ-SDH) from Arabidopsis thaliana with IC50 values of 2.1 ± 0.3 µM and 2.0 ± 0.2 µM, respectively.
11
Alarcon, Alejandra, Wilda Olivares, Maria Jose Maturana, et al. "Combined use of methylated reprimo cell-free DNA and pepsinogens for noninvasive detection of early gastric cancer." Journal of Clinical Oncology 33, no. 3_suppl (2015): 27. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.27.
Full textAbstract:
27 Background: Gastric cancer (GC) has been described as a multistep cascade of precursor lesions such as non-atrophic chronic gastritis (NACG), multiphocal atrophic gastritis (MAG), intestinal metaplasia (IM), low grade dysplasia (LGD) and high grade dysplasia (HGD) leading to early stages of GC (EGC). Currently, no non-invasive biomarkers for this progression are clinically available. We have previously identified a potential biomarker based on methylated Reprimo (RPRM) cell-free DNA (cfDNA) (Clin Cancer Res 2008;14:6264-9). In a cross-sectional study of 1,076 patients, we showed a sensitivity of 70.8% (95% CI: 60.3 to 81.3) and specificity of 74.3% (95% CI: 71.5 to 77) for methylated RPRM cfDNA, to distinguish NACG+MAG+IM+LGD vs HGD+EGC+AGC (Digestive Disease Week 2014 #108). However, the crude detection rate of EGC was only 46.6%. Here, we aim to explore the role of the combined use of methylated RPRM cfDNA and well stablished atrophy biomarkers such as pepsinogens, for non-invasive detection of EGC. Methods: A case-control study was performed including 237 patients (NACG:40; MAG:94; IM:55; LGD:11; HGD:5: EGC:15; AGC:17) scheduled for upper gastrointestinal endoscopy (UGIE). A heparinized venous blood sample was collected and methylated RPRM cfDNA and Immunoassays for Pepsinogen I and II were performed. Positive value was considered if methylated RPRM cfDNA > 0 copies/mL and PG I/II ratio <3.0 were found. Results: Overall sensitivity and specificity for the combined use of methylated RPRM cfDNA and PGI/II to distinguish NACG+MAG+IM+LGD vs HGD+EGC+AGC was 67.5% (95% CI: 50.2% to 81.9%) and 63% (95% CI: 55.9% to 69.7%), respectively. Positive and negative predictive values were 25.2% (95% CI: 17% to 34.9%) and 91.3% (95% CI: 85.3% to 95.4%), respectively. Importantly, crude detection rate for EGC increased from 46.6% to 86.7%. Conclusions: The combined use of methylated RPRM cfDNA and PGI/II reached similar sensitivity and specificity compared to methylated RPRM cfDNA alone to distinguish NACG+MAG+IM+LGD vs HGD+EGC+AGC. However, combined use of methylated RPRM cfDNA and PGI/II significantly improved the detection rate of EGC, a lesion with a curability rate over 95%.
12
Vázquez Cisneros, Lucía Cristina, Patricia López-Uriarte, Antonio López-Espinoza, Mónica Navarro Meza, Ana Cristina Espinoza-Gallardo, and Martha Beatriz Guzmán Aburto. "Efectos del té verde y su contenido de galato de epigalocatequina (EGCG) sobre el peso corporal y la masa grasa en humanos. Una revisión sistemática." Nutrición Hospitalaria 34, no. 3 (2017): 731. http://dx.doi.org/10.20960/nh.753.
Full textAbstract:
La prevalencia e incidencia del sobrepeso y la obesidad continúan en aumento a nivel mundial, así como las enfermedades relacionadas con estas condiciones. Ello se atribuye a un incremento en la ingesta de energía y una disminución en el gasto de la misma. El consumo de té verde se ha relacionado con una reducción en la grasa y el peso corporal. Sin embargo, las investigaciones realizadas con el té verde han sido muy diversas. Esta revisión sistemática explora las investigaciones que se han realizado con té verde y su contenido de galato de epigalocatequina (EGCG) evaluando su efecto sobre la grasa y el peso corporal en humanos. Se realizó una búsqueda en las bases de datos PubMed y Web of Science que dio como primer resultado un total de 424 artículos potenciales. Fueron excluidos 409, por lo que se utilizaron 15 artículos para esta revisión sistemática. Las investigaciones han sido muy diversas; sin embargo, el consumo diario de té verde con dosis de EGCG entre los 100 y los 460 mg/día ha mostrado mayor efectividad sobre la reducción de masa grasa y peso corporal en periodos de intervención de 12 semanas o más. Además, la utilización de dosis de cafeína entre 80 y 300 mg/día ha mostrado ser un factor de importancia para los efectos obtenidos, siempre y cuando los participantes no tuviesen previo a la intervención una ingesta habitual de cafeína alta (> 300 mg/día).
13
Preall, Richard J., and Neil H. Ringler. "Comparison of Actual and Potential Growth Rates of Brown Trout (Salmo trutta) in Natural Streams Based on Bioenergetic Models." Canadian Journal of Fisheries and Aquatic Sciences 46, no. 6 (1989): 1067–76. http://dx.doi.org/10.1139/f89-138.
Full textAbstract:
A ratio of specific growth rate to predicted maximum growth rate was employed as an ecological growth coefficient (EGC) in identifying major determinants of growth for brown trout, Salmo trutta, in natural streams. The coefficient may be more useful than specific growth rate when comparing trout populations from streams having diverse characteristics, since it accounts for the quantitative effects of stream temperature and mean trout weight. The maximum growth rate was generated by translating Elliott's bioenergetic equations into computer models applicable to fish weighing 5–300 g and to stream temperatures of 3.8–21.7 °C. EQMAX is the simpler model and generates only maximum growth rate. TROUT estimates the maximum ration size, maximum growth rate, and a variety of bioenergetic parameters. The EGC for Age I + trout ranged from 60 to 90% in three central New York streams. A relatively low EGC (30–60%) observed for Age II + trout in one stream may have been due to the inefficiency of feeding on small invertebrates. Temperature appears to be a dominant feature governing trout growth in streams. The bioenergetic models may provide useful predictions of the effects of foraging on prey communities by brown trout.
14
Braal, C. Louwrens, Koen G. A. M. Hussaarts, Lieke Seuren, et al. "Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen." Breast Cancer Research and Treatment 184, no. 1 (2020): 107–13. http://dx.doi.org/10.1007/s10549-020-05829-6.
Full textAbstract:
Abstract Background Many cancer patients use additional herbs or supplements in combination with their anti-cancer therapy. Green tea—active ingredient epigallocatechin-3-gallate (EGCG)—is one of the most commonly used dietary supplements among breast cancer patients. EGCG may alter the metabolism of tamoxifen. Therefore, the aim of this study was to investigate the influence of green tea supplements on the pharmacokinetics of endoxifen; the most relevant active metabolite of tamoxifen. Methods In this single-center, randomized cross-over trial, effects of green tea capsules on endoxifen levels were evaluated. Patients treated with tamoxifen for at least 3 months were eligible for this study. After inclusion, patients were consecutively treated with tamoxifen monotherapy for 28 days and in combination with green tea supplements (1 g twice daily; containing 300 mg EGCG) for 14 days (or vice versa). Blood samples were collected on the last day of monotherapy or combination therapy. Area under the curve (AUC0–24h), maximum concentration (Cmax) and minimum concentration (Ctrough) were obtained from individual plasma concentration–time curves. Results No difference was found in geometric mean endoxifen AUC0–24h in the period with green tea versus tamoxifen monotherapy (− 0.4%; 95% CI − 8.6 to 8.5%; p = 0.92). Furthermore, no differences in Cmax (− 2.8%; − 10.6 to 5.6%; p = 0.47) nor Ctrough (1.2%; − 7.3 to 10.5%; p = 0.77) were found. Moreover, no severe toxicity was reported during the whole study period. Conclusions This study demonstrated the absence of a pharmacokinetic interaction between green tea supplements and tamoxifen. Therefore, the use of green tea by patients with tamoxifen does not have to be discouraged.
15
Plemel, Jason R., Camille A. Juzwik, Curtis A. Benson, Michael Monks, Chelsea Harris, and Michelle Ploughman. "Over-the-counter anti-oxidant therapies for use in multiple sclerosis: A systematic review." Multiple Sclerosis Journal 21, no. 12 (2015): 1485–95. http://dx.doi.org/10.1177/1352458515601513.
Full textAbstract:
Background: Anti-oxidant compounds that are found in over-the-counter (OTC) supplements and foods are gaining interest as treatments for multiple sclerosis (MS). They are widely used by patients, sometimes without a clear evidence base. Objective: We conducted a systematic review of animal and clinical research to determine the evidence for the benefits of OTC anti-oxidants in MS. Methods: Using predefined criteria, we searched key databases. Two authors scrutinized all studies against inclusion/exclusion criteria, assessed study risk-of-bias and extracted results. Results: Of the 3507 titles, 145 met criteria and included compounds, α(alpha)-lipoic acid (ALA), anti-oxidant vitamins, Ginkgo biloba, quercetin, resveratrol and epigallocatechin-3-gallate (ECGC). The strongest evidence to support OTC anti-oxidants was for compounds EGCG and ALA in animal models; both consistently showed anti-inflammatory/anti-oxidant effects and reduced neurological impairment. Only vitamin E, Ginkgo biloba and ALA were examined for efficacy in pilot clinical trials with either conflicting evidence or evidence of no benefit. Conclusion: OTC anti-oxidants EGCG and ALA show the most consistent benefit, however only in preclinical studies. There is no evidence that they alter MS relapses or progression. Future work should focus on testing more of these therapies for clinical efficacy before recommending them to MS patients.
16
ter Veer, Emil, Jessy Joy van Kleef, Sandor Schokker, et al. "Prognostic and predictive factors for overall survival (OS) in metastatic esophagogastric cancer (EGC): A meta-analysis." Journal of Clinical Oncology 35, no. 15_suppl (2017): 4048. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4048.
Full textAbstract:
4048 Background: Prognostic and predictive factors for metastatic EGC are important to estimate prognosis, inform clinical decision-making and design future trials. We performed a systematic review with meta-analysis to identify these factors. Methods: We searched Medline, EMBASE and CENTRAL for phase 2/3 randomized controlled trials (RCTs) until January 2016 on palliative chemotherapy and targeted therapy for metastatic EGC. Prognostic and predictive factors were identified from respectively multivariate cox regressions and stratified treatment comparisons. Hazard Ratio’s (HR) for OS were extracted and pooled with meta-analysis if possible. Prognostic factors were considered independent if the multivariate HR was significant (P≤0.05). Predictive factors were clinically relevant if P for subgroup interaction was ≤0.20 and the HR in one of the subgroups was significant (P≤0.05). Results: We identified 47 RCTs (14,853 patients), wherein 54 potential prognostic and 40 predictive factors were reported. Eight independent prognostic factors for poor OS reported in ≥2 RCTs based on ≥300 patients were: performance status of ≥1 vs 0 (pooled HR, 95% confidence interval: 1.47, 1.25-1.73) or 2 vs 0-1 (1.52, 1.32-1.76); metastatic vs locally advanced disease (1.55, 1.39-1.72); diffuse vs intestinal/other histology (1.38, 1.12-1.71); ≥3 vs < 2 metastatic sites (1.35, 1.07-1.70); presence of metastases in peritoneum (1.24, 1.01-1.51) or liver (1.45 (1.28-1.64); measurable vs non-measurable disease (1.31, 1.04-1.66); and no prior vs prior surgery (1.33, 1.16-1.53). Predictive factors for specific treatment comparisons based on ≥300 patients were: age (≥65 vs < 65); performance status; tumor location (GEJ vs stomach); disease stage; number of metastatic sites; peritoneal metastasis; measurable disease; histology; HER2; KRAS; VEGF A; and Neuropilin-1 for first line treatments; and time to progression on first line therapy ( < 3, 3-6 or ≥6 months) for second-line treatments. Conclusions: Eight independent prognostic factors for OS and thirteen clinically relevant predictive factors for treatment efficacy of EGC were found.
17
Okimoto, Kenichiro, Makoto Arai, Hideaki Ishigami, et al. "Renal Dysfunction is a Risk Factor of Death after Gastric Endoscopic Submucosal Dissection in Elderly Patients Aged ≥80 Years." Canadian Journal of Gastroenterology and Hepatology 2019 (September 9, 2019): 1–9. http://dx.doi.org/10.1155/2019/7145182.
Full textAbstract:
Introduction. Endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) is well accepted. However, its adaptation for elderly patients is unclear. This study aimed to investigate the prognosis and long-term outcomes of ESD for EGC in elderly patients aged ≥80 years by comparing their findings to the findings of patients aged <80 years. Materials and Methods. The study included 533 patients (632 lesions). The patients were divided into an elderly group (age, ≥80 years; 108 patients; 128 lesions; mean age, 83.4 ± 2.7 years) and a nonelderly group (age, <80 years; 425 patients; 504 lesions; mean age, 69.6 ± 7.9 years). We compared patient and lesion characteristics, overall survival (OS), and disease-specific survival (DSS) between the 2 groups retrospectively. Multivariate analysis was performed to clarify the risk factors of death after ESD. Results. The rate of curative resection and adverse events was not significantly different between the groups. The mean survival time periods with regard to OS/DSS in the elderly and nonelderly groups were 75.8 ± 5.9 and 122.8 ± 2.6 months (P<0.05)/120.0 ± 3.0 and 136.4 ± 0.6 months (not significant), respectively. In the elderly group, eGFR <30 ml/min/1.73 m2 was an independent risk factor of death (hazard ratio = 5.32; 95% confidence interval = 1.39–20.5; P=0.015). Conclusion. ESD for EGC can be performed safely and can achieve high curability with good prognosis in elderly patients aged ≥80 years. After ESD, close attention should be paid to elderly patients with severe chronic kidney disease.
18
Purwanto, Djoko Agus, Retno Pudji Rahayu, and A. Toto Purnomo. "ANALYSIS OF IFN- CONCENTRATION IN WISTAR RAT BLOOD AFTER ORAL ADMINISTRATION OF STANDARDIZED GREEN TEA WATER EXTRACT." Indonesian Journal of Chemistry 10, no. 3 (2010): 390–95. http://dx.doi.org/10.22146/ijc.21448.
Full textAbstract:
Green tea and its polyphenols have been studied extensively as cancer chemopreventive agents in recent years. However, the mechanisms of action are still not clearly understood. Some researchers suggest that immune system plays important role to destroy cancer cells. Because of that reason, the present study was designed to analyse the effects of oral administration standardized green tea water extract on increasing of IFN-g blood concentration and to elucidate possible mechanisms involved in the inhibitory action of the cancer development. Two groups (male and female) of 5 rats have given p.o. administration 1.25% of standardized green tea water extract and got 300 mg of (-)-epigallocatechin gallate (EGCG)/kg body weight, while two groups others (male and female) were used as control. We found that IFN-g blood concentration on male and female Wistar rat are significantly increase with 13.11% and 17.59%, respectively (p
19
Roberts, Justin D., Ashley G. B. Willmott, Liam Beasley, et al. "The Impact of Decaffeinated Green Tea Extract on Fat Oxidation, Body Composition and Cardio-Metabolic Health in Overweight, Recreationally Active Individuals." Nutrients 13, no. 3 (2021): 764. http://dx.doi.org/10.3390/nu13030764.
Full textAbstract:
This study investigated the effect of decaffeinated green tea extract (dGTE), with or without antioxidant nutrients, on fat oxidation, body composition and cardio-metabolic health measures in overweight individuals engaged in regular exercise. Twenty-seven participants (20 females, 7 males; body mass: 77.5 ± 10.5 kg; body mass index: 27.4 ± 3.0 kg·m2; peak oxygen uptake (V.O2peak): 30.2 ± 5.8 mL·kg−1·min−1) were randomly assigned, in a double-blinded manner, either: dGTE (400 mg·d−1 (−)-epigallocatechin−3-gallate (EGCG), n = 9); a novel dGTE+ (400 mg·d−1 EGCG, quercetin (50 mg·d−1) and α-lipoic acid (LA, 150 mg·d−1), n = 9); or placebo (PL, n = 9) for 8 weeks, whilst maintaining standardised, aerobic exercise. Fat oxidation (‘FATMAX’ and steady state exercise protocols), body composition, cardio-metabolic and blood measures (serum glucose, insulin, leptin, adiponectin, glycerol, free fatty acids, total cholesterol, high [HDL-c] and low-density lipoprotein cholesterol [LDL-c], triglycerides, liver enzymes and bilirubin) were assessed at baseline, week 4 and 8. Following 8 weeks of dGTE+, maximal fat oxidation (MFO) significantly improved from 154.4 ± 20.6 to 224.6 ± 23.2 mg·min−1 (p = 0.009), along with a 22.5% increase in the exercise intensity at which fat oxidation was deemed negligible (FATMIN; 67.6 ± 3.6% V.O2peak, p = 0.003). Steady state exercise substrate utilisation also improved for dGTE+ only, with respiratory exchange ratio reducing from 0.94 ± 0.01 at week 4, to 0.89 ± 0.01 at week 8 (p = 0.004). This corresponded with a significant increase in the contribution of fat to energy expenditure for dGTE+ from 21.0 ± 4.1% at week 4, to 34.6 ± 4.7% at week 8 (p = 0.006). LDL-c was also lower (normalised fold change of −0.09 ± 0.06) for dGTE+ by week 8 (p = 0.038). No other significant effects were found in any group. Eight weeks of dGTE+ improved MFO and substrate utilisation during exercise, and lowered LDL-c. However, body composition and cardio-metabolic markers in healthy, overweight individuals who maintained regular physical activity were largely unaffected by dGTE.
20
Lehuger, S., B. Gabrielle, E. Larmanou, P. Laville, P. Cellier, and B. Loubet. "Predicting the global warming potential of agro-ecosystems." Biogeosciences Discussions 4, no. 2 (2007): 1059–92. http://dx.doi.org/10.5194/bgd-4-1059-2007.
Full textAbstract:
Abstract. Nitrous oxide, carbon dioxide and methane are the main biogenic greenhouse gases (GHG) contributing to the global warming potential (GWP) of agro-ecosystems. Evaluating the impact of agriculture on climate thus requires a capacity to predict the net exchanges of these gases in an integrated manner, as related to environmental conditions and crop management. Here, we used two year-round data sets from two intensively-monitored cropping systems in northern France to test the ability of the biophysical crop model CERES-EGC to simulate GHG exchanges at the plot-scale. The experiments involved maize and rapeseed crops on a loam and rendzina soils, respectively. The model was subsequently extrapolated to predict CO2 and N2O fluxes over an entire crop rotation. Indirect emissions (IE) arising from the production of agricultural inputs and from cropping operations were also added to the final GWP. One experimental site (involving a wheat-maize-barley rotation on a loamy soil) was a net source of GHG with a GWP of 350 kg CO2-C eq ha−1 yr−1, of which 75% were due to IE and 25% to direct N2O emissions. The other site (involving an oilseed rape-wheat-barley rotation on a rendzina) was a net sink of GHG for –250 kg CO2-C eq ha−1 yr−1, mainly due to a higher predicted C sequestration potential and C return from crops. Such modelling approach makes it possible to test various agronomic management scenarios, in order to design productive agro-ecosystems with low global warming impact.
21
Nilam, Mohamed, Philip Gribbon, Jeanette Reinshagen, et al. "A Label-Free Continuous Fluorescence-Based Assay for Monitoring Ornithine Decarboxylase Activity with a Synthetic Putrescine Receptor." SLAS DISCOVERY: Advancing the Science of Drug Discovery 22, no. 7 (2017): 906–14. http://dx.doi.org/10.1177/2472555216689288.
Full textAbstract:
Polyamines play an important role in cell growth, differentiation, and cancer development, and the biosynthetic pathway of polyamines is established as a drug target for the treatment of parasitic diseases, neoplasia, and cancer chemoprevention. The key enzyme in polyamine biosynthesis is ornithine decarboxylase (ODC). We report herein an analytical method for the continuous fluorescence monitoring of ODC activity based on the supramolecular receptor cucurbit[6]uril (CB6) and the fluorescent dye trans-4-[4-(dimethylamino)styryl]-1-methylpyridinium iodide (DSMI). CB6 has a significantly higher binding constant to the ODC product putrescine (>107 M−1) than to the substrate L-ornithine (340 M−1). This enables real-time monitoring of the enzymatic reaction through a continuous fluorescence change caused by dye displacement from the macrocycle by the formed product, which allowed a straightforward determination of enzyme kinetic parameters ( kcat = 0.12 s−1 and KM = 24 µM) and inhibition constants of the two ODC inhibitors α-difluoromethylornithine (DFMO) and epigallocatechin gallate (EGCG). The potential for high-throughput screening (HTS) was demonstrated by excellent Z′ factors (>0.9) in a microplate reader format, and the sensitivity of the assay is comparable to or better than most established complementary methods, which invariably have the disadvantage of not being compatible with direct implementation and upscaling to HTS format in the drug discovery process.
22
Rondanelli, Mariangela, Antonella Riva, Giovanna Petrangolini, et al. "Effect of Acute and Chronic Dietary Supplementation with Green Tea Catechins on Resting Metabolic Rate, Energy Expenditure and Respiratory Quotient: A Systematic Review." Nutrients 13, no. 2 (2021): 644. http://dx.doi.org/10.3390/nu13020644.
Full textAbstract:
The consumption of green tea catechins (GTC) is associated with modulations of fat metabolism and consequent weight loss. The aim of this systematic review was to investigate the effect of GTC on resting metabolic rate (RMR), energy expenditure (EE), and respiratory quotient (RQ). Eligible studies considered both the chronic and acute intake of GTC-based supplements, with epigallocatechin gallate (EGCG) doses ranging between 100–800 mg. Findings from 15 studies (n = 499 participants) lasting 8–12 weeks (for chronic consumption) or 1–3 days (for acute intake) are summarized. This review reveals the positive effects of GTC supplementation on RQ values (272 subjects). Regarding the effects of acute and chronic GTC supplementation on RMR (244 subjects) and EE (255 subjects), the results did not allow for a definitive conclusion, even though they were promising, because some reported a positive improvement (two studies revealed an increase in RMR: one demonstrated an RMR increase of 43.82 kcal/day and another demonstrated an increase of 260.8 kcal/day, mainly when subjects were also engaged in resistance training exercise). Considering GTC daily dose supplementation, studies in which modifications of energetic parameters occurred, in particular RQ reduction, considered GTC low doses (100–300 mg). GTC may be useful for improving metabolic profiles. Further investigations are needed to better define adequate doses of supplementation.
23
Ku, Geoffrey Yuyat, Francisco Sanchez-Vega, Walid Chatila, et al. "Correlation of benefit from immune checkpoint inhibitors with next gen sequencing (NGS) profiles in esophagogastric cancer (EGC) patients." Journal of Clinical Oncology 35, no. 15_suppl (2017): 4025. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4025.
Full textAbstract:
4025 Background: Immuno-oncology (IO) with anti-PD-1 and –PD-L1 antibodies (Abs) is active in EGC but only benefits a minority of Pts. Biomarkers are needed to identify responders. Methods: We reviewed our experience of Pts treated with anti-PD-1/PD-L1 Abs and correlated their outcomes with PD-L1 and mismatch repair protein (MMR) status by immunohistochemistry (IHC), as well as MSK-IMPACT (≥340-gene) NGS profile. MSIsensor from IMPACT assesses microsatellite instability phenotype, while ≥20 mutations (or 17 mutations/Mb) strongly correlates with MMR-deficiency (dMMR) by IHC (J Clin Oncol 2016;34:2141). Progression-free (PFS) and overall survival (OS) were analyzed from the start of IO. Results: 71 Pts were identified, with 3 Pts receiving 2 IO regimens. 66 had adenoCAs and 5 had squamous CAs. Median age 58, 77% male, 96% had received ≥2 prior chemo regimens. 39 (55%), 18 (25%) and 17 Pts (24%) respectively received anti-PD-1, anti-PD-L1 and anti-CTLA-4 plus anti-PD-1/PD-L1 Abs. 6 Pts (8%) had objective response (2 complete responses or CRs) and the median PFS and OS are 1.6 and 4.7 mos; 2-yr OS is 17%. PD-L1 IHC was performed in 16 Pts (23%; 7 +ve), MMR was tested in 20 Pts (28%; 4 dMMR) and IMPACT was obtained in 44 Pts (62%). All 4 dMMR tumors were also MSI by MSIsensor and had a median of 46 mutations (range, 29-63) or, equivalently, 33 mutations/Mb (range, 21-46); 2 of 2 dMMR tumors tested PD-L1 +ve. 3 of the 4 Pts with dMMR/MSI tumors had a response (including 1 CR) and the median OS of these 4 Pts is not reached with 23+ months of follow-up. Finally, a patient whose tumor is MMR-proficient, not MSI but has 15 mutations (including in POLD1), achieved an ongoing CR at 37+ mos. For the 44 Pts with IMPACT testing, there appeared to be improved OS for tumors with ≥10 vs. <10 mutations/Mb (2-yr OS 80% vs. 12%, p=0.03). Conclusions: Pts with tumors that are MSI or have ≥10 mutations/Mb on MSK-IMPACT appear to derive significant benefit from IO. MSK-IMPACT can offer novel information, identify novel mutations (e.g. POLD1) and may be used to help select Pts for IO. We are seeking to define a mutation no. cut-off that can serve as a biomarker and updated data will be presented.
24
Zhang, Xue-Qiong, Jin-Hwa Kim, Geun-Soo Lee, et al. "In Vitro Antioxidant and In Vivo Anti-Inflammatory Activities of Ophioglossum thermale." American Journal of Chinese Medicine 40, no. 02 (2012): 279–93. http://dx.doi.org/10.1142/s0192415x1250022x.
Full textAbstract:
Antioxidant fractions from Ophioglossum thermale were extracted with five different polar solvents using a Soxhlet type extractor. The total phenolic content of the extracts was determined by the Folin-Ciocalteu method. The ethyl acetate fraction of O. thermale was found to contain maximum phenolics. The dried fractions were screened for their antioxidant activity potential using in vitro model systems such as 1,1-diphenyl-2-picryl hydrazyl (DPPH), nitroblue tetrazolium (NBT) and lipid-peroxidation reduction at different concentrations. Results revealed that the EtOAc fraction exhibited the best performance in the DPPH assay, NBT assay and lipid peroxidation. All fractions showed more potent antioxidant capacity than green tea extract, a well-known antioxidant. Furthermore, the EtOAc fraction has the highest total phenolic content (475.65 mg of EGCG/g). In addition, the EtOAc fraction at 0.005% and 0.01% (g/100 ml) also significantly inhibited UVB irradiation-induced ROS generation in human dermal fibroblasts (HDFs). In a carrageenan-induced edema model, the EtOAc fraction showed an inhibitory effect (21.5%, p < 0.05) at 200 mg/kg (p.o.) after 300 min administration. Consequently, 3-O-methylquercetin (3MQ) was also isolated from the antioxidative EtOAc fraction. The data obtained using the above in vitro and in vivo tests suggest that the antioxidant activity of O. thermale and its anti-inflammatory effect on carrageenan-induced acute inflammation can be attributed to its ameliorating effect on oxidative damage, and thus it has great potential as a source for natural health products. To the best of our knowledge, this is the first report on the antioxidant activity of different polar extracts from O. thermale.
25
Samavat, Hamed, Talia Philippsborn, Mindy Kurzer, and Diane Rigassio Radler. "The Effect of Green Tea Extract on Individual Components of Metabolic Syndrome in Women Who Are Post-menopause." Current Developments in Nutrition 5, Supplement_2 (2021): 367. http://dx.doi.org/10.1093/cdn/nzab037_077.
Full textAbstract:
Abstract Objectives Green tea intake may have a role in weight management and glucose control. Given the rise in prevalence of metabolic syndrome (MetS) among aging women, research regarding green tea's effect on MetS is warranted. This study aimed to determine whether green tea extract (GTE) supplementation improves components of MetS among women who are post-menopause. Methods This study was a secondary analysis of the Minnesota Green Tea Trial (MGTT), a double-blinded randomized controlled trial. Participants were a subset of the MGTT who had MetS at baseline. Participants were instructed to take four GTE capsules containing a mean (SD) 843 (44) mg epigallocatechin gallate (EGCG) or placebo daily for 12 months. Waist circumference, HDL-cholesterol, triglyceride, fasting blood glucose, diastolic and systolic blood pressure levels were measured at baseline and month 12, and changes were compared and stratified by catechol-O-methyltransferase enzyme (COMT) genotype, BMI, and the number of antihypertensive medications. One-way and two-way ANCOVA tests adjusting for age and BMI at baseline were also used for comparisons of the endpoints between treatment groups and for exploratory analyses. Results The GTE group (n = 49) experienced a significant reduction in HDL-cholesterol concentrations compared to an increase in the placebo group (n = 63) (GTE: −0.45 ± 1.27 mg/dL, Placebo: 2.95 ± 0.77 mg/dL, P = 0.04). Those in the GTE group with high-activity COMT genotype had a significant reduction in SBP compared to placebo. (Low/intermediate-activity COMT genotype GTE: −0.79 ± 2.08 mmHg, Placebo: −3.26 ± 1.67 mmHg; High-activity COMT genotype GTE: −5.64 ± 2.73 mmHg, Placebo: 1.58 ± 3.00 mmHg, P-interaction = 0.048). Those in the GTE group who took three antihypertensive medications had a significant reduction in waist circumference compared to placebo (GTE: −7.91 ± 3.72cm, placebo: 3.50 ± 2.64 cm, P-interaction = 0.04). No significant changes were found for the other endpoints. Conclusions GTE supplementation for 12 months was not associated with improvements in individual components of MetS in this population. GTE supplementation may help reduce SBP among women with high-activity COMT genotype and waist circumference in those who take three antihypertensive medications. Funding Sources NIH/National Cancer Institute.
26
Pinheiro, V., A. Souza, R. Ereno, and C. Barros. "23 PREGNANCY RATE IN NELORE COWS AFTER TEMPORARY CALF REMOVAL, AND USE OF HORMONAL PROTOCOLS WITH eCG." Reproduction, Fertility and Development 17, no. 2 (2005): 161. http://dx.doi.org/10.1071/rdv17n2ab23.
Full textAbstract:
Both temporary calf removal (TCR) and administration of eCG are potentially useful to improve pregnancy rates in animals treated with fixed-time artificial insemination (FTAI) protocols. In the present work, two experiments were performed to compare the efficiency of eCG and/or TCR in FTAI protocols, with or without exogenous progesterone. In experiment 1, lactating Nelore cows (40 to 70 days post-partum, n = 220) were allocated to two Groups. At a random stage of the estrous cycle (Day 0), animals from Group GPE (GnRH/PGF2α/Estradiol)/eCG were treated with GnRH (50 mg lecireline, i.m.; Gestran Plus®; Tecnopec, Sao Paulo, Brazil). Seven days later (Day 7) they received PGF2α (150 mg D-cloprostenol, i.m.; Prolise®, Tecnopec) and eCG (300 UI, i.m.; Novormon®, Syntex). On Day 8 estradiol benzoate (EB, 1 mg, Estrogin®, Tecnopec) was administered, and 30–36 h later the animals were inseminated (FTAI). In Group DIB (bovine intravaginal device)/eCG an intravaginal progesterone-releasing device (1.0 g, DIB®, Syntex, Buenos Aires, Agrentina; Day 0) was inserted into the vagina of cows and EB (2.5 mg, i.m.) was given in parallel. Eight days later (Day 8), eGC (300 UI, i.m.) and D-cloprostenol (150 mg) were administered. Then the DIB was removed. Twenty-four hour after DIB removal, cows were treated with EB (1.0 mg, i.m.), and 30–36 h later the animals were inseminated (FTAI). Ultrasonographic evaluation of ovaries was performed in all experiments 10 days before and at the beginning of the treatments or TCR, in order to detect the presence of CL. Cows from Group DIB/eCG showed higher pregnancy rates than those from Group GPE/eCG (58%, 72/124 vs. 39.5%, 38/96, respectively, P < 0.01). Furthermore, only in Group GPE/eCG were pregnancy rates higher in animals with CL (47.6%, 20/42) when compared to those without CL (33%, 18/54, P < 0.05). In a second experiment, a possibly beneficial effect of TCR on GPE/eCG protocol was tested in lactating Nelore cows (40 to 70 days postpartum, n = 140). Animals of Group GPE/eCG (control) were treated as described above, whereas calves were removed for 48 h from cows in Group RTB/GPE/eCG prior to hormonal treatments. Lactating Nelore cows having their calves removed showed a significant increase in pregnancy rates compared to those without TCR (51.2%, 34/66 v. 28.4%, 21/74, respectively, P < 0.01), in both situations: animals with CL (54.8%, 17/31 v. 33.3%, 11/33, respectively, RTB/GPE/eCG v. GPE/eCG) or without CL (48.5%, 17/35 v. 24.3%, 10/41, respectively, RTB/GPE/eCG v. GPE/eCG). In conclusion, these results indicate that addition of eCG to the GPE protocol was not efficient enough to produce comparable results to those obtained with DIB/eCG protocol. However, calf removal before the GPE/eCG treatment increased pregnancy rates in cycling or anestrous (without CL) lactating Nelore cows.
27
Bazyar, Hadi, Seyed Ahmad Hosseini, Sirous Saradar, et al. "Effects of epigallocatechin-3-gallate of Camellia sinensis leaves on blood pressure, lipid profile, atherogenic index of plasma and some inflammatory and antioxidant markers in type 2 diabetes mellitus patients: a clinical trial." Journal of Complementary and Integrative Medicine, December 24, 2020. http://dx.doi.org/10.1515/jcim-2020-0090.
Full textAbstract:
Abstract Background In patients with type 2 diabetes mellitus (T2DM) the inflammatory and metabolic responses to epigallocatechin-3-gallate (EGCG) are unknown. Objectives Evaluate the impacts of EGCG on metabolic factors and some biomarkers of stress oxidative in patients with T2DM. Methods In this randomized, double-blind, placebo-controlled trial, 50 patients with T2DM consumed either 2 tablets (300 mg) EGCG (n=25) or wheat flour as placebo (n=25) for 2 months. The total antioxidant capacity (TAC), interleukin-6 (IL-6), lipid profile, mean arterial pressure (MAP), atherogenic index of plasma (AIP) were evaluated before and after the intervention. Results The finding of present study exhibited a significant increase in the serum levels of TAC after the EGCG supplementation (p=0.001). Also, in compare with control group, the mean changes of TAC were significantly higher in supplement group (p=0.01). In intervention group, a significant decrease was observed in the mean levels of triglyceride, total cholesterol, diastolic blood pressure (DBP), AIP, and MAP (p<0.05). Taking EGCG resulted in the mean changes of total cholesterol, MAP and DBP were significantly lower in compare with control group (p<0.05). Conclusions This study recommended that EGCG supplementation may be improved blood pressure, lipid profile, AIP, and oxidative status in patients with T2DM.
28
ANWAR, EFFIONORA, and SHIFA RIZKAMIARTY. "FORMULATION AND EVALUATION OF COSMETIC FOUNDATION USING EPIGALLOCATECHIN GALLATE AS A SUN PROTECTION." International Journal of Applied Pharmaceutics, March 21, 2020, 130–34. http://dx.doi.org/10.22159/ijap.2020.v12s1.ff029.
Full textAbstract:
Objective: The objective of the study was to obtain a lotion foundation using epigallocatechin gallate (EGCG) as an active ingredient designed with asun protection factor (SPF) value around 30 that can effectively protect facial skin from ultraviolet radiation (UVR) exposure and that is safe to use.Methods: In this study, we determine SPF value using UV–visible spectrophotometry at a wavelength between 290 and 320 nm. The preparationformula of the foundation was made with an EGCG concentration of 0.4%, a concentration which can yield the desired SPF value of about 30. Physicalstability was performed at low (4±2°C), ambient (25±2°C), and high (40±2°C) temperatures; cycling and centrifugation tests were also conducted.Safety was evaluated by eye irritation test using hen’s egg test on chorioallantois method and skin irritation test using the Draize and patch testsmethod.Results: The SPF values of 0.04% EGCG and lotion foundation containing 0.4% EGCG were 31.02±0.72 and 33.20±0.59, respectively. The results ofcycling and centrifugal tests indicated that lotion foundation showed an absence of crystals and lack of any phase separation between oil and waterphases. The physical stability test showed no significant changes for all parameters. Safety tests resulted in neither skin nor eye irritation.Conclusion: The EGCG foundation developed was physically stable with a good appearance and did not irritate the skin or eyes thus are safe to usealso can effectively protect skin against UVR exposure.
29
Zidane, Nora, Mohamed B. Ould-Abeih, Isabelle Petit-Topin, and Hugues Bedouelle. "The folded and disordered domains of human ribosomal protein SA have both idiosyncratic and shared functions as membrane receptors." Bioscience Reports 33, no. 1 (2012). http://dx.doi.org/10.1042/bsr20120103.
Full textAbstract:
The human RPSA [ribosomal protein SA; also known as LamR1(laminin receptor 1)] belongs to the ribosome but is also a membrane receptor for laminin, growth factors, prion, pathogens and the anticarcinogen EGCG (epigallocatechin-gallate). It contributes to the crossing of the blood–brain barrier by neurotropic viruses and bacteria, and is a biomarker of metastasis. RPSA includes an N-terminal domain, which is folded and homologous to the prokaryotic RPS2, and a C-terminal extension, which is intrinsically disordered and conserved in vertebrates. We used recombinant derivatives of RPSA and its N- and C-domains to quantify its interactions with ligands by in-vitro immunochemical and spectrofluorimetric methods. Both N- and C-domains bound laminin with KD (dissociation constants) of 300 nM. Heparin bound only to the N-domain and competed for binding to laminin with the negatively charged C-domain, which therefore mimicked heparin. EGCG bound only to the N-domain with a KD of 100 nM. Domain 3 of the envelope protein from yellow fever virus and serotypes-1 and -2 of dengue virus bound preferentially to the C-domain whereas that from West Nile virus bound only to the N-domain. Our quantitative in-vitro approach should help clarify the mechanisms of action of RPSA, and ultimately fight against cancer and infectious agents.